{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:18Z","timestamp":1761901338133,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.msard.2018.09.014","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T12:39:26Z","timestamp":1537619966000},"page":"192-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety liver profile of teriflunomide versus interferon \u03b2 in multiple sclerosis: Systematic review and indirect comparison meta-analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-6103","authenticated-orcid":false,"given":"Paola Andrea Ortiz","family":"Salas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Olarte","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo Pinzon","family":"Florez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina Maria","family":"Goez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Velez-van-Meerbeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus Hernan","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.09.014_bib0001","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1212\/CON.0000000000000324","article-title":"New approaches to the diagnosis, clinical course, and goals of therapy in multiple sclerosis and related disorders","volume":"22","author":"Krieger","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2018.09.014_bib0002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis - a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2018.09.014_bib0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1756285615598910","article-title":"Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis","volume":"8","author":"Farber","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2018.09.014_bib0004","doi-asserted-by":"crossref","first-page":"i3518","DOI":"10.1136\/bmj.i3518","article-title":"Disease modifying therapies for relapsing multiple sclerosis","volume":"354","author":"Wingerchuk","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2018.09.014_bib0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11940-015-0354-5","article-title":"The transition from first-line to second-line therapy in multiple sclerosis","volume":"17","author":"D\u00f6rr","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2018.09.014_bib0006","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.014_bib0007","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB multiple sclerosis study group and the University of British Columbia MS\/MRI analysis group","volume":"45","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.014_bib0008","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"(Prevention of relapses and disability by interferon beta-1a suncutaneously in multiple sclerosis) study group. Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.09.014_bib0009","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)","volume":"359","author":"Durelli","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.msard.2018.09.014_bib0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.09.014_bib0011","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.62.4.628","article-title":"Liver injury associated with the beta-interferons for MS: a comparison between the three products","volume":"62","author":"Tremlett","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.014_bib0012","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00002018-200326110-00006","article-title":"Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance","volume":"26","author":"Francis","year":"2003","journal-title":"Drug Saf."},{"key":"10.1016\/j.msard.2018.09.014_bib0013","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis. Chill maz (HB, PT) \u2014 both fr stock (TPO)","volume":"14365","author":"O \u2019Connor","year":"2011","journal-title":"Sanofi-Aventis N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.09.014_bib0014","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.09.014_bib0015","first-page":"1","article-title":"Annex I - Teriflunomide summary of product characteristics","author":"Morris","year":"2009","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.msard.2018.09.014_bib0016","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2018.09.014_bib0017","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.09.014_bib0018","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.09.014_bib0019","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"AJ","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2018.09.014_bib0020","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.09.014_bib0021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2011.08.013","article-title":"Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study","volume":"312","author":"De Stefano","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.09.014_bib0022","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2018.09.014_bib0023","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the rebif vs glatiramer acetate in relapsing ms disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.09.014_bib0024","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250\u202f??G or 500\u202f??G interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'Connor","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.09.014_bib0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2018.09.014_bib0026","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1177\/1352458512436594","article-title":"Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years","volume":"18","author":"Confavreux","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2018.09.014_bib0027","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.clinthera.2008.06.013","article-title":"Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 \u03bcg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study","volume":"30","author":"Hurwitz","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.msard.2018.09.014_bib0028","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1471-2377-12-154","article-title":"Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferon\u03b2-1a versus subcutaneous interferon\u03b2-1b: results of the randomized, multicenter, Phase IIIb REFORMS study","volume":"12","author":"Singer","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2018.09.014_bib0029","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.014_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2013.09.005","article-title":"Evaluation of abnormal liver tests","volume":"98","author":"Woreta","year":"2014","journal-title":"Med. Clin. North Am."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:42Z","timestamp":1761900162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":30,"alternative-id":["S2211034818303262"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.014","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety liver profile of teriflunomide versus interferon \u03b2 in multiple sclerosis: Systematic review and indirect comparison meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}